Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases.
Hongyu XuLin ZhouYou LuXiaomei SuPeng ChengDong LiHui GaoHua LiWeiwei YuanLing ZhangTao ZhangPublished in: OncoTargets and therapy (2020)
Leptomeningeal metastases (LM) occur in 3-5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- magnetic resonance imaging
- tyrosine kinase
- end stage renal disease
- newly diagnosed
- ejection fraction
- diffusion weighted imaging
- contrast enhanced
- chronic kidney disease
- papillary thyroid
- prognostic factors
- small cell lung cancer
- cerebrospinal fluid
- peritoneal dialysis
- computed tomography
- squamous cell carcinoma
- brain metastases
- magnetic resonance
- drug delivery
- cancer therapy
- sleep quality
- squamous cell
- lymph node metastasis